Mechanism AMY1A inhibitors [+2] |
Active Org.- |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Cell differentiation stimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2020 |
Sponsor / Collaborator |
Start Date11 Dec 2018 |
Sponsor / Collaborator |
Start Date19 Sep 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BTI-320 ( AMY1A x MGAM x Peptide hydrolase ) | Diabetes Mellitus, Type 2 More | Discontinued |
Human proislet peptide | Diabetes Mellitus, Type 1 More | Pending |
CDM-1102 | Diabetes Mellitus More | Pending |
CDM-1103 | Obesity More | Pending |